Drug intelligence / Profile preview

3-methoxybenzamide

Development stage: Unknown
Modality: Small Molecules

Overview

3-Methoxybenzamide is a small molecule belonging to the benzamide class of organic compounds. It features a methoxy group at the meta position relative to the amide group on a benzene ring. This compound has been studied primarily as an experimental inhibitor of poly [ADP-ribose] polymerase 1 (PARP1), an enzyme involved in DNA repair processes. By inhibiting PARP1, it can interfere with cellular responses to DNA damage and has been explored for its potential biological activity in pharmaceutical research and as a tool compound in biochemical studies. There are no approved therapeutic indications or marketed formulations for this substance[1][7].

Other names: m-anisamidem-methoxybenzamidebenzamide 3-methoxy-benzamide3-methoxy-benzamide-3-methoxy-3-methoxy-benzamide

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on 3-methoxybenzamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3-methoxybenzamide.

Explore the full profile